TABLE 1

Demographics of patients with Achromobacter sp. infectiona

ParameterValue for groupP valued
Total (n = 34)Transient infection (n = 24)Persistent infection (n = 10)Controls (n = 18)Transient infection vs persistent infectionPersistent infection vs controls
Median age (IQR)24 (20.3–29.8)25 (21.0–30.3)24 (19.3–27.3)22 (18.0–25.8)0.800.45
No. (%) of males15 (44.1)9 (37.5)6 (60.0)11 (61.1)0.230.95
Median BMI (IQR)20 (18.3–21.4)20 (18.4–21.1)19 (18.2–21.8)21 (19.2–23.1)0.760.50
No. (%) of patients with pancreatic insufficiency29 (85.3)20 (83.3)9 (90.0)13 (72.2)0.620.27
Median FVC% (IQR)73 (56.3–95.8)69 (56.8–102.3)75 (54.8–85.5)86 (64.8–104.8)0.250.11
Median FEV1% (IQR)51 (35.5–81.3)47 (34.5–87.3)57 (38.3–75.5)66 (43.3–88.5)0.630.22
No. (%) of patients with home O24 (11.8)3 (12.5)1 (10.0)0 (0.0)0.840.17
No. (%) of patients who received:
    Inhaled tobramycinb7 (20.6)5 (20.8)2 (20.0)4 (22.2)0.960.89
    Azithromycinb4 (11.8)3 (12.5)1 (10.0)4 (22.2)0.840.42
    Inhaled corticosteroid8 (23.5)3 (12.5)5 (50.0)3 (16.7)0.020.06
No. (%) of patients with chronic coinfection
    P. aeruginosa28 (82.4)20 (83.3)8 (80.0)12 (66.6)0.820.45
    S. aureus25 (73.5)17 (70.8)8 (80.0)7 (38.8)0.580.04
No. (%) of patients with comorbidityc
    CFRD5 (14.7)3 (12.5)2 (20.0)3 (16.7)0.570.83
    Sinus disease10 (29.4)6 (25.0)4 (40.0)10 (55.6)0.380.43
    Bone disease9 (26.5)7 (29.2)2 (20.0)4 (22.2)0.580.89
    CFLD8 (23.5)6 (25.0)2 (20.0)2 (11.1)0.750.52
    DIOS3 (8.8)3 (12.5)0 (0.0)2 (11.1)0.240.27
  • a Baseline data are from the 2 years prior to incident Achromobacter culture. Note that the “persistent” cohort included a 10th patient who was unable to be compared to control patients for clinical outcomes.

  • b Azithromycin or tobramycin use at time of Achromobacter sp. culture or control study entry.

  • c CFRD, CF-related diabetes; CFLD, CF liver disease; DIOS, distal intestinal obstruction syndrome.

  • d Values in bold indicate those which were statistically significant.